報價延遲最少15分鐘:2025/02/13 13:43 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
12.375 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.65/--
|
|
企業價值
--
|
| 資產負債 |
|
每股賬面淨值
不適用
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
--
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/02/13 13:43 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which haveinitiated a Phase 3 clinical trial for hyperphagia associated with PWS. |